Startup Nula Emerges to Advance a New Class of Medicines for Metabolic Disease
The fatty liver disease MASH is one of the metabolic disorders that Nula Therapeutics is pursuing. The startup’s small molecules are intended to restore the integrity of the nuclear envelope, a cellular membrane whose dysfunction can contribute to metabolic disease.